[Translation] An open-label, multicenter, single-arm phase IIIb confirmatory clinical study evaluating the efficacy, safety and tolerability of britinib in patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 mutations

在未接受过MET抑制剂治疗， MET外显子14突变的局部晚期/转移性NSCLC患者中，通过独立评审委员会（IRC）评估的确认的客观缓解率（ORR）评价伯瑞替尼的疗效

[Translation]

In MET inhibitor-naïve patients with locally advanced/metastatic NSCLC with MET exon 14 mutations, the efficacy of bricitinib was evaluated by confirmed objective response rate (ORR) assessed by an independent review committee (IRC)

Start Date25 Sep 2023

Sponsor / Collaborator

Beijing Purunao Biotechnology Co Ltd

CTR20232728 / CompletedNot Applicable

伯瑞替尼肠溶胶囊在空腹给药条件下随机、开放、两制剂、三周期、三交叉的人体生物等效性试验

[Translation] Randomized, open-label, two-preparation, three-period, three-crossover human bioequivalence study of britinib enteric-coated capsules under fasting administration conditions

主要研究目的考察健康受试者在空腹条件下，单次口服3粒经生产场地变更后的伯瑞替尼肠溶胶囊（受试制剂T，规格：100mg/粒）或3粒生产场地变更前的伯瑞替尼肠溶胶囊（参比制剂R，规格：100mg/粒）的药动学特征，评价两制剂间的生物等效性。次要研究目的观察健康受试者空腹条件下单次口服受试制剂与参比制剂伯瑞替尼肠溶胶囊的安全性。

[Translation]

Main research purpose Investigate healthy subjects under fasting conditions, orally orally 3 capsules of britinib enteric-coated capsules (test preparation T, specification: 100mg/capsule) after the change of production site or 3 capsules of Buritinib before the change of production site Pharmacokinetic characteristics of Tini enteric-coated capsules (reference preparation R, specification: 100mg/capsule), and evaluate the bioequivalence between the two preparations. Secondary research purpose To observe the safety of single oral administration of the test preparation and the reference preparation britinib enteric-coated capsules under fasting conditions in healthy subjects.

Start Date04 Sep 2023

Sponsor / Collaborator

Beijing Purunao Biotechnology Co Ltd

NCT05989542 / Active, not recruitingPhase 3

An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation

The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are:
If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation
If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation
Participants will
1. be given PLB1001 200mg BID,oral.
2. be received hematology and urine and ECG examinations every 14 days (First 3 months) or every 28 days (After 3 months)
3. be received Image examination every 8 weeks(First year) or every 12 weeks(After one year)

Start Date29 Jun 2023

Sponsor / Collaborator

Beijing Purunao Biotechnology Co Ltd

100 Clinical Results associated with Vebreltinib

100 Translational Medicine associated with Vebreltinib

100 Patents (Medical) associated with Vebreltinib

Literatures (Medical) associated with Vebreltinib

14 Jul 2023·Chinese neurosurgical journal

PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial.

Article

Author: Zhang, Bisi ; Wang, Liang ; Qiu, Xiaoguang ; Jiang, Tao ; Shi, Hepeng ; Bao, Zhaoshi ; Li, Shouwei ; Zhang, Peilong

BACKGROUNDPTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib. However, little is known about the further efficacy of vebreltinib among more glioma patients. This trial aims to evaluate the safety and efficacy of vebreltinib enteric-coated capsules in the treatment of sGBM/IDH mutant glioblastoma patients with the ZM fusion gene.METHODSThis multicentric, randomized, open-label, controlled trial plans to include 19 neurosurgical centers and recruit 84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene. This trial enrolls sGBM or IDH mutant glioblastoma patients with the inclusion criteria and without the exclusion criteria. It was registered with chinadrugtrials.org.cn (CTR20181664). The primary efficacy endpoint is overall survival (OS). The secondary endpoints are progression-free survival (PFS) and objective response rate (ORR).DISCUSSIONIf proven effective, this targeted multifaceted intervention protocol will be extended for more glioma patients as a protocol to evaluate the safety and efficacy of MET inhibitors.TRIAL REGISTRATIONIt was registered with chinadrugtrials.org.cn (CTR20181664).

01 Oct 2021·Journal for ImmunoTherapy of CancerQ2 · MEDICINE

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas

Q2 · MEDICINE

ArticleOA

Author: Ren, Chang-Yuan ; Jiang, Tao ; Wang, Zhi-Liang ; Bao, Zhao-Shi ; Ma, Wen-Ping ; Wang, Zheng ; Zhao, Zheng ; Zhang, Ying ; Li, Shou-Wei ; Wang, Kuan-Yu ; Sun, Li-Hua ; Li, Guan-Zhang ; Xu, Jian-Bao ; Zhu, Yong-Jian ; Wang, Hong-Jun ; Wang, Qiang-Wei

BackgroundDysregulated receptor tyrosine kinases, such as the mesenchymal-epidermal transition factor (MET), have pivotal role in gliomas. MET and its interaction with the tumor microenvironment have been previously implicated in secondary gliomas. However, the contribution of MET gene to tumor cells’ ability to escape immunosurveillance checkpoints in primary gliomas, especially in glioblastoma (GBM), which is a WHO grade 4 glioma with the worst overall survival, is still poorly understood.MethodsWe investigated the relationship between MET expression and glioma microenvironment by using multiomics data and aimed to understand the potential implications of MET in clinical practice through survival analysis. RNA expression data from a total of 1243 primary glioma samples (WHO grades 2–4) were assembled, incorporating The Cancer Genome Atlas, Chinese Glioma Genome Atlas, and GSE16011 data sets.ResultsPearson’s correlation test from the three data sets indicated that MET showed a robust correlation with programmed death-ligand 1 (PD-L1) and STAT pathways. Western blot analysis revealed that in GBM cell lines (N33 and LN229), PD-L1 and phosphorylated STAT4 were upregulated by MET activation treatment with hepatocyte growth factor and were downregulated on MET suppression by PLB-1001. Tumor tissue microarray analysis indicated a positive correlation between MET and PD-L1 and macrophage-associated markers. Chromatin immunoprecipitation-PCR assay showed enrichment of STAT4 in the PD-L1 DNA. Transwell co-culture and chemotaxis assays revealed that knockdown of MET in GBM cells inhibited macrophage chemotaxis. Moreover, we performed CIBERSORTx and single-cell RNA sequencing data analysis which revealed an elevated number of macrophages in glioma samples with MET overexpression. Kaplan-Meier survival analysis indicated that activation of the MET/STAT4/PD-L1 pathway and upregulation of macrophages were associated with shorter survival time in patients with primary GBM.ConclusionsThese data indicated that the MET-STAT4-PD-L1 axis and tumor-associated macrophages might enforce glioma immune evasion and were associated with poor prognosis in GBM samples, suggesting potential clinical strategies for targeted therapy combined with immunotherapy in patients with primary GBM.

01 Nov 2018·CellQ1 · BIOLOGY

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

Q1 · BIOLOGY

Article

Author: Qiu, Xiaoguang ; Fan, Xiaolong ; Chen, Jing ; Zeng, Fan ; Jiang, Tao ; Nam, Yoonhee ; Cho, Hee-Jin ; Wang, Zhiliang ; Sa, Jason K ; Jiang, Biaobin ; Liu, Yuqing ; Wang, Qiangwei ; Zhang, Wei ; Wang, Kuanyu ; Wu, Fan ; Chen, Yiyun ; Nam, Do-Hyun ; Li, Wenbin ; Wang, Zheng ; Hu, Huimin ; Kang, Xun ; Zhang, Ying ; Qian, Zenghui ; Zhao, Zheng ; Her, Nam-Gu ; Mu, Quanhua ; Bao, Zhaoshi ; Wang, Jiguang ; Huang, Ruoyu ; Zhang, Chuanbao ; Liu, Yanwei

Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fusion and is present in ∼14% of cases with significantly worse prognosis. Subsequent studies show that METex14 promotes glioma progression by prolonging MET activity. Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models. Importantly, this compound also shows blood-brain barrier permeability and is subsequently applied in a phase I clinical trial that enrolls MET-altered chemo-resistant glioma patients. Encouragingly, PLB-1001 achieves partial response in at least two advanced sGBM patients with rarely significant side effects, underscoring the clinical potential for precisely treating gliomas using this therapy.

News (Medical) associated with Vebreltinib

08 May 2024

·www.globenewswire.com

Apollomics Announces Private Placement Financing and Addition to Board of Directors

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financing included participation from both new and existing investors. Pursuant to the terms of the subscription agreements, Apollomics is selling an aggregate of 19,166,666 Class A ordinary shares at a price of $0.30 per share. The PIPE financing is expected to close on May 8, 2024, subject to satisfaction of customary closing conditions. Apollomics intends to use the net proceeds from the PIPE financing, together with the Apollomics’ existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital. Apollomics also announced today the appointment of Dr. Robert (Bob) Lin, M.D., Ph.D. to the board of directors of Apollomics. Dr. Lin is a physician and researcher who has conducted multinational clinical trials and is experienced in genomics, proteomics and biotech transactions. Dr. Lin has served as the vice director of the Internal Medicine Department at a tertiary medical center in Taiwan and conducted post-doctoral research at Lawrence Berkeley Laboratory in the United States. In addition, Jonathan Wang, Ph.D. has resigned from the board of directors, due to personal reasons. “On behalf of Apollomics, we welcome Dr. Lin to the company. He brings valuable medical and biotech experience to our Board,” said Dr. Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “I would like to thank Dr. Wang for his impactful leadership and his valuable contributions to the company over the last eight years, and wish him well in his future endeavors.” Canaccord Genuity is acting as financial advisor to Apollomics for the PIPE financing. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Pursuant to the subscription agreements, the Company has agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the Class A ordinary shares sold in the PIPE financing. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Apollomics Inc.Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking StatementsThis press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding the closing of the PIPE financing, clinical trials and results, as well as the Company’s strategy, business plans and objectives of management are forward-looking statements. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) Apollomics’ ability to raise additional capital to meet its operating cash requirements and expectations regarding incurring net losses and net operating cash outflows; (ii) the ability of Apollomics to maintain the listing of its Class A ordinary shares on Nasdaq (iii) Apollomics’ ability to achieve successful clinical results; (iv) Apollomics’ ability to commercialize its product candidates; (v) Apollomics’ ability to develop and maintain effective internal controls over financial reporting; (vi) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations; (vii) Apollomics’ ability to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (viii) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; and other risks included in the Annual Report on Form 20-F filed with the SEC and other SEC filings that are available publicly on the SEC’s website at www.sec.gov. Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. CONTACTSInvestor RelationsPeter VozzoICR WestwickePeter.Vozzo@westwicke.com+1-443-213-0505 Media RelationsSean LeousICR WestwickeSean.Leous@westwicke.com+1-646-866-4012

Executive Change

26 Apr 2024

·www.globenewswire.com

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial April 25, 2024 -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. (Avistone), received approval from the National Medical Products Administration (NMPA) of China for vebreltinib (APL-101) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration, and follows the NMPA’s November 2023 approval of vebreltinib for the treatment of patients with Met Exon 14 skipping non-small cell lung cancer (NSCLC). "The NMPA’s approval of vebreltinib in gliomas is an important, first-in-class approval as it demonstrates vebreltinib’s CNS penetration ability and c-Met inhibitory activity in the tumors there," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. "Our collaboration with Avistone, which includes data-sharing, and our ongoing global SPARTA trial with vebreltinib underscores our commitment and the potential to develop vebreltinib for treating patients with solid tumors with c-Met alterations globally, outside of China.” Gliomas are difficult-to-treat primary malignant intracranial tumors accounting for about 46% of all intracranial tumors. Surgery, radiation treatment, and chemotherapy are current standard treatment strategies for gliomas with poor prognoses. The overall survival (OS) rate for malignant glioma patients is less than 10% after five years. Prior studies in Chinese patients have found that about 12% of gliomas have MET fusion, among which the representative type ZM fusion occurs in about 14% of glioblastomas with a history of lower-grade disease, often co-occurring with Met Exon 14 skipping mutations, and is associated with a poorer prognosis. The proportion of this glioblastoma genotype in the U.S. and EU is less known. Vebreltinib, Apollomics’ most advanced product candidate in the U.S., is a potent, small molecule, orally bioavailable and highly selective c-Met inhibitor that works by inhibiting the aberrant activation of the HGF/c-Met axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies. The approval of vebreltinib for the ZM fusion-positive glioma indication in China is based on the positive results of Avistone’s FUGEN study (NCT06105619), a randomized, two-arm, multicenter Phase 2/3 clinical study that was conducted in China. This 84-patient study compared the efficacy and safety of vebreltinib with the dose-dense regimen of temozolomide or the combination of etoposide and cisplatin, with OS as the primary endpoint. The median OS for the vebreltinib monotherapy regimen was 6.31 months, compared to 3.38 months for the control group, reducing the risk of death by 48% and significantly improving the survival of patients with recurrent relapsing ZM fusion glioma, with an acceptable safety profile. In the ongoing global SPARTA study being conducted by Apollomics that includes U.S. and European patients, similar to the vebreltinib treated patients in the FUGEN study in China, a median survival of 6.5 months has been observed to date in the 25 patients with recurrent relapsing CNS tumors with c-Met alterations treated with vebreltinib. Eight of these 25 patients with recurrent relapsing glioma had centrally confirmed ZM fusion glioma, where the median OS was also 6.5 months. These preliminary data support cross-region similarity of patient response to treatment with vebreltinib. Under the partnership agreement, Avistone holds the exclusive rights to vebreltinib in China, Hong Kong and Macau, while Apollomics retains the exclusive rights in the rest of the world, including the U.S, and the partners have access to each other’s data. This collaboration enables both companies to leverage their strengths and maximize the benefit of vebreltinib worldwide. Apollomics is conducting a multi-cohort Phase 2 study of vebreltinib, SPARTA, at over 90 centers in 12 countries investigating the efficacy and safety of vebreltinib in Met Exon 14 skipping NSCLC. Cohorts A-1 is recruiting in first line Met Exon 14 skipping NSCLC subjects and Cohort A-2 is recruiting in pretreated (> 2L) Met Exon 14 skipping NSCLC subjects. In addition, Cohort C includes histology agnostic c-Met amplified cancers (excluding primary CNS tumors) and Cohort C-1 includes NSCLC harboring c-Met amplification and wild-type epidermal growth factor receptor (EGFR). About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical ResultRadiation Therapy

25 Apr 2024

·www.biospace.com

Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China

BEIJING--(BUSINESS WIRE)-- Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred to as PLB1001, APL-101, bozitinib, CBT-101) from the Chinese National Medical Products Administration (NMPA) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant Astrocytoma (World Health Organization grade 4) with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration. In November 2023, vebreltinib received conditional approval for the treatment of metastatic patients with MET Exon14 Skipping non-small cell lung cancer (NSCLC) from the NMPA. Glioma is a refractory primary malignant intracranial tumor, accounting for approximately 46% of intracranial tumors [1]. Surgery, radiotherapy and chemotherapy are current standard treatment strategies for gliomas, and the prognosis is poor. The 5-year overall survival (OS) rate of patients with malignant glioma is less than 10% [2]. In previous studies in Chinese patients, about 12% of brain gliomas were found to have MET fusion [3]. Among the representative type PTPRZ1-MET fusion gene (hereinafter referred to as ZM fusion) occurs in about 14% of glioblastomas with a history of lower-grade disease, often co-occurring with MET Exon 14 skipping mutations and is associated with poor prognosis [3-4]. The approval of vebreltinib for the ZM fusion-positive glioma indications is based on the positive results of the FUGEN study (NCT06105619). The FUGEN study is a randomized controlled, open label, multicenter clinical registration phase II/III study. This 84-patient study compared the efficacy and safety of vebreltinib with the dose-dense regimen of temozolomide or the combination of etoposide and cisplatin, with OS as the primary endpoint. The median OS for the vebreltinib monotherapy regimen was 6.31 months, compared to 3.38 months for the control group, reducing the risk of death by 48% and significantly improving the survival of patients with recurrent relapsing ZM fusion glioma, with an acceptable safety profile. "The development of drugs for indications related to MET targets has always been a difficult one. This is not only a victory for translational medicine, but also marks the advent of the era of targeted therapy in the field of brain glioma,” said Dr. Hepeng Shi, Chairman, CEO, and Founder of Avistone. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone) is an innovative biotechnology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive portfolio and pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and in other solid tumors. References: [1] Louis D N. Annu Rev Pathol, 2006, 1: 97-117. [2] Qi Y, et al. Front Immunol. 2020 Nov 27;11:578877. [3] Guo R, et al. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. [4] Hu H, et al. Cell. 2018 Nov 29;175(6):1665-1678.e18. View source version on businesswire.com: Contacts David Chung Chief Business Officer david.chung@avistonebio.com Source: Avistone Biotechnology Co., Ltd. View this news release online at:

Drug ApprovalClinical Result

100 Deals associated with Vebreltinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Astrocytoma, IDH-Mutant	CN	Beijing Purunao Biotechnology Co Ltd	17 Apr 2024
Glioblastoma	CN	Beijing Purunao Biotechnology Co Ltd	17 Apr 2024
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	CN	Beijing Purunao Biotechnology Co Ltd	14 Nov 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thyroid Cancer	Phase 2	US	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	ES	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	SG	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	TW	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	GB	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	IT	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	FI	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	CA	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	FR	Apollomics, Inc. (United States)	27 Sep 2017
Thyroid Cancer	Phase 2	HU	Apollomics, Inc. (United States)	27 Sep 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02896231 (AACR2020) Manual	Phase 1	Non-Small Cell Lung Cancer MET Mutation	37	bozitinib	(tpduhdymtw) = cohemqimqf ppnefnkujs (ypqfgqnqvq ) View more	Positive	15 Aug 2020
NCT04258033 \| NCT03175224 (KUNPENG \| SPARTA, Biospace) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	500	Vebreltinib (gene copy number<4)	(txnzovwntl) = xrivocifzn zonoupnzlo (ziauptogdc ) View more	Positive	04 Dec 2023
	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	500	Vebreltinib (GCN≥4)	(txnzovwntl) = lmiazbhije zonoupnzlo (ziauptogdc ) View more	Positive	04 Dec 2023
NCT02896231, NCT02276027 (ASCO2017)	Not Applicable	Non-Small Cell Lung Cancer MET \| PIK3CA	568	Bozitinib	(zwgpdytxje) = two mice died because of the toxicities in the crizotinib+taselisib group bpmzlisaun (ytgcwtllzh )	Positive	30 May 2017
NCT04258033 (KUNPENG, ESMO2023) Manual	Phase 2	c-Met positive non-small cell lung cancer MET Exon 14 Mutation	52	Vebreltinib 200 mg	(oqrwateygf) = decikqpmjc fphagbiopt (ivtgqksyyg, 61.1 ～ 86.0) View more	Positive	23 Oct 2023
NCT04258033 (KUNPENG, ESMO2023) Manual	Phase 2		52	Vebreltinib 200 mg (treatment-naïve pts)	(oqrwateygf) = eswazslsua fphagbiopt (ivtgqksyyg, 59.9～89.6) View more	Positive	23 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vebreltinib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation